{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:19:04Z","timestamp":1792873144810,"version":"4.5.0"},"reference-count":215,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002632","name":"Hallym University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2017R1A2B4012944"],"award-info":[{"award-number":["NRF-2017R1A2B4012944"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2020R1C1C1008694"],"award-info":[{"award-number":["NRF-2020R1C1C1008694"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ymthe.2020.09.028","type":"journal-article","created":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T10:32:43Z","timestamp":1600597963000},"page":"571-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":276,"title":["CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases"],"prefix":"10.1016","volume":"29","author":[{"given":"Garima","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Ranjan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manojit","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiranjib","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.09.028_bib1","first-page":"341","article-title":"CRISPR for neuromuscular disorders: gene editing and beyond","volume":"34","author":"Young","year":"2019","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.ymthe.2020.09.028_bib2","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2174\/1389450117666160527142321","article-title":"The smart programmable CRISPR technology: a next generation genome editing tool for investigators","volume":"18","author":"Chakraborty","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ymthe.2020.09.028_bib3","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.09.028_bib4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/febs.13586","article-title":"Potential pitfalls of CRISPR\/Cas9-mediated genome editing","volume":"283","author":"Peng","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.ymthe.2020.09.028_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.biotechadv.2014.12.006","article-title":"The CRISPR\/Cas9 system for plant genome editing and beyond","volume":"33","author":"Bortesi","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ymthe.2020.09.028_bib6","series-title":"CRISPR-Cas9 genome engineering in Saccharomyces cerevisiae cells. Cold Spring Harb. Protoc. 2016. 10.1101\/pdb.prot086827","author":"Ryan","year":"2016"},{"key":"10.1016\/j.ymthe.2020.09.028_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nmeth.2532","article-title":"Heritable genome editing in C.\u00a0elegans via a CRISPR-Cas9 system","volume":"10","author":"Friedland","year":"2013","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.09.028_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/0471142727.mb3102s111","article-title":"CRISPR-Cas9 genome editing in Drosophila","volume":"111","author":"Gratz","year":"2015","journal-title":"Curr. Protoc. Mol. Biol"},{"key":"10.1016\/j.ymthe.2020.09.028_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00439-016-1739-6","article-title":"CRISPR\/Cas9 in zebrafish: an efficient combination for human genetic diseases modeling","volume":"136","author":"Liu","year":"2017","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.09.028_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4939-7237-1_11","article-title":"Genome-wide CRISPR\/Cas9 screening for high-throughput functional genomics in human cells","volume":"1656","author":"Zhu","year":"2017","journal-title":"Methods Mol. Biol"},{"key":"10.1016\/j.ymthe.2020.09.028_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1126\/science.341.6148.833","article-title":"The CRISPR craze","volume":"341","author":"Pennisi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib13","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1093\/nar\/gku241","article-title":"Classification and evolution of type II CRISPR-Cas systems","volume":"42","author":"Chylinski","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib14","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1126\/science.1159689","article-title":"Small CRISPR RNAs guide antiviral defense in prokaryotes","volume":"321","author":"Brouns","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMra1800729","article-title":"A new class of medicines through DNA editing","volume":"380","author":"Porteus","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib18","first-page":"309","article-title":"First-in-human phase 1 CRISPR gene editing cancer trials: are we ready?","volume":"17","author":"Baylis","year":"2017","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nature.2016.20302","article-title":"Chinese scientists to pioneer first human CRISPR trial","volume":"535","author":"Cyranoski","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.028_bib20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nmeth.4293","article-title":"Unexpected mutations after CRISPR-Cas9 editing in\u00a0vivo","volume":"14","author":"Schaefer","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.09.028_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/420116a","article-title":"A tragic setback","volume":"420","author":"Check","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.028_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1126\/science.299.5606.495","article-title":"Gene therapy. Seeking the cause of induced leukemias in X-SCID trial","volume":"299","author":"Kaiser","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ymthe.2020.09.028_bib24","doi-asserted-by":"crossref","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T\u00a0cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib26","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1126\/science.286.5448.2244","article-title":"Gene therapy death prompts review of adenovirus vector","volume":"286","author":"Marshall","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1126\/science.1079512","article-title":"Enhancing gene targeting with designed zinc finger nucleases","volume":"300","author":"Bibikova","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1534\/genetics.110.120717","article-title":"Targeting DNA double-strand breaks with TAL effector nucleases","volume":"186","author":"Christian","year":"2010","journal-title":"Genetics"},{"key":"10.1016\/j.ymthe.2020.09.028_bib29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen","year":"2002","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev.biophys.29.1.183","article-title":"DNA recognition by Cys2His2 zinc finger proteins","volume":"29","author":"Wolfe","year":"2000","journal-title":"Annu. Rev. Biophys. Biomol. Struct."},{"key":"10.1016\/j.ymthe.2020.09.028_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nmeth.1539","article-title":"Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures","volume":"8","author":"Doyon","year":"2011","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.09.028_bib32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nmeth0508-374","article-title":"Unexpected failure rates for modular assembly of engineered zinc fingers","volume":"5","author":"Ramirez","year":"2008","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.09.028_bib33","first-page":"S104","article-title":"CHAMPIONS: a phase 1\/2 clinical trial with dose escalation of SB-913 ZFN-mediated in\u00a0vivo human genome editing for treatment of MPS II (Hunter syndrome)","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2020.09.028_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/COH.0b013e32834122d7","article-title":"Chemokine receptor 5 knockout strategies","volume":"6","author":"Cannon","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ymthe.2020.09.028_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ydbio.2015.11.003","article-title":"CRISPR\/Cas9: an inexpensive, efficient loss of function tool to screen human disease genes in Xenopus","volume":"408","author":"Bhattacharya","year":"2015","journal-title":"Dev. Biol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib37","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1038\/s41598-017-07871-9","article-title":"CRISPR\/Cas9-mediated genome editing efficiently creates specific mutations at multiple loci using one sgRNA in Brassica napus","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.028_bib39","doi-asserted-by":"crossref","first-page":"44061","DOI":"10.18632\/oncotarget.6392","article-title":"ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts","volume":"6","author":"Valletta","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2020.09.028_bib40","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","article-title":"An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in\u00a0vivo","volume":"10","author":"Aubrey","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jor.22745","article-title":"Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system","volume":"33","author":"Feng","year":"2015","journal-title":"J.\u00a0Orthop. Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2016.04.046","article-title":"SHCBP1 is over-expressed in breast cancer and is important in the proliferation and apoptosis of the human malignant breast cancer cell line","volume":"587","author":"Feng","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2020.09.028_bib43","doi-asserted-by":"crossref","first-page":"e0152820","DOI":"10.1371\/journal.pone.0152820","article-title":"Upregulation of KLHDC4 predicts a poor prognosis in human nasopharyngeal carcinoma","volume":"11","author":"Lian","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2020.09.028_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.15252\/emmm.201506006","article-title":"CRISPR\/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy","volume":"8","author":"Tang","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib45","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/gt.2015.53","article-title":"CRISPR-Cas9-mediated gene knockout in primary human airway epithelial cells reveals a proinflammatory role for MUC18","volume":"22","author":"Chu","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.intimp.2010.04.014","article-title":"Janus kinase-3 dependent inflammatory responses in allergic asthma","volume":"10","author":"Malaviya","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib47","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib48","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.2174\/13816128113199990313","article-title":"Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies","volume":"19","author":"Seidah","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2020.09.028_bib49","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease","volume":"127","author":"Yang","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.09.028_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.scr.2016.08.002","article-title":"Generation of a gene-corrected isogenic control cell line from an Alzheimer\u2019s disease patient iPSC line carrying a A79V mutation in PSEN1","volume":"17","author":"Pires","year":"2016","journal-title":"Stem Cell Res. (Amst.)"},{"key":"10.1016\/j.ymthe.2020.09.028_bib51","first-page":"8","article-title":"The potential of CRISPR\/Cas9 gene editing as a treatment strategy for Alzheimer\u2019s disease","volume":"8","author":"Rohn","year":"2018","journal-title":"J.\u00a0Alzheimers Dis. Parkinsonism"},{"key":"10.1016\/j.ymthe.2020.09.028_bib52","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in\u00a0vivo genome base editing in adult mice","volume":"24","author":"Villiger","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/hum.2014.111","article-title":"Fanconi anemia gene editing by the CRISPR\/Cas9 system","volume":"26","author":"Osborn","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib54","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1074\/jbc.RA117.000347","article-title":"Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats","volume":"293","author":"Shao","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2020.09.028_bib55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-017-0489-9","article-title":"Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing","volume":"10","author":"Wen","year":"2017","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib56","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1101\/gr.173427.114","article-title":"Seamless gene correction of \u03b2-thalassemia mutations in patient-specific iPSCs using CRISPR\/Cas9 and piggyBac","volume":"24","author":"Xie","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib57","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2020.09.028_bib58","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/mt.2015.220","article-title":"In\u00a0vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa","volume":"24","author":"Bakondi","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib59","doi-asserted-by":"crossref","first-page":"BIO34","DOI":"10.1167\/iovs.16-21287","article-title":"CRISPR\/Cas9-mediated mutation of \u03b1A-crystallin gene induces congenital cataracts in rabbits","volume":"58","author":"Yuan","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.09.028_bib60","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/srep02510","article-title":"Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus","volume":"3","author":"Ebina","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib62","first-page":"2197","article-title":"CRISPR\/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6","volume":"17","author":"Yoshiba","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ymthe.2020.09.028_bib63","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","article-title":"Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus","volume":"3","author":"Chen","year":"2018","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib64","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2020.09.028_bib65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.09.028_bib66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12935-015-0221-1","article-title":"Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp","volume":"15","author":"Alfarouk","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ymthe.2020.09.028_bib67","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.09.028_bib68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc3950","article-title":"Applications of the CRISPR-Cas9 system in cancer biology","volume":"15","author":"S\u00e1nchez-Rivera","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2020.09.028_bib69","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1038\/ncomms6393","article-title":"Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.09.028_bib70","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-12-304","article-title":"Myeloid malignancies: mutations, models and management","volume":"12","author":"Murati","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ymthe.2020.09.028_bib71","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/sj.leu.2402416","article-title":"MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis","volume":"16","author":"Craig","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2020.09.028_bib72","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.7150\/jca.32628","article-title":"Cyclin-dependent kinases 4\/6 inhibitors in breast cancer: current status, resistance, and combination strategies","volume":"10","author":"Niu","year":"2019","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.ymthe.2020.09.028_bib73","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.1038\/srep10433","article-title":"Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth","volume":"5","author":"Zhou","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib74","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","article-title":"CDK7-dependent transcriptional addiction in triple-negative breast cancer","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.09.028_bib75","doi-asserted-by":"crossref","first-page":"83502","DOI":"10.18632\/oncotarget.13148","article-title":"Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2020.09.028_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-7364-7-13","article-title":"Update on the Kelch-like (KLHL) gene family","volume":"7","author":"Dhanoa","year":"2013","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.ymthe.2020.09.028_bib77","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00335-017-9703-x","article-title":"Modeling human disease in rodents by CRISPR\/Cas9 genome editing","volume":"28","author":"Birling","year":"2017","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.ymthe.2020.09.028_bib78","doi-asserted-by":"crossref","first-page":"43331","DOI":"10.1038\/srep43331","article-title":"Efficient and rapid generation of large genomic variants in rats and mice using CRISMERE","volume":"7","author":"Birling","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib79","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.cell.2015.02.038","article-title":"Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis","volume":"160","author":"Chen","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.09.028_bib80","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.3802","article-title":"Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids","volume":"21","author":"Matano","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib81","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1038\/ncomms8391","article-title":"Somatic CRISPR\/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling","volume":"6","author":"Zuckermann","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.09.028_bib82","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.2951","article-title":"Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing","volume":"32","author":"Heckl","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib84","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib86","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T\u00a0cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib87","doi-asserted-by":"crossref","DOI":"10.1177\/2155179018822781","article-title":"Approval of first CAR-Ts: have we solved all hurdles for ATMPs?","volume":"11","author":"Seimetz","year":"2019","journal-title":"Cell Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib88","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/oxfordjournals.epirev.a036028","article-title":"Morbidity as a focus of preventive health care in the elderly","volume":"10","author":"Fried","year":"1988","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.ymthe.2020.09.028_bib89","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib90","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T\u00a0cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib91","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2017.1241711","article-title":"CRISPR\/Cas9 in allergic and immunologic diseases","volume":"13","author":"Goodman","year":"2017","journal-title":"Expert Rev. Clin. Immunol"},{"key":"10.1016\/j.ymthe.2020.09.028_bib92","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ajpath.2012.11.005","article-title":"A novel function of MUC18: amplification of lung inflammation during bacterial infection","volume":"182","author":"Wu","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib93","doi-asserted-by":"crossref","first-page":"20070","DOI":"10.1038\/srep20070","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T\u00a0cells from cancer patients","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib94","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-3083.2010.02386.x","article-title":"Primary immunodeficiency and autoimmunity: lessons from human diseases","volume":"71","author":"Arason","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib95","doi-asserted-by":"crossref","first-page":"AB17","DOI":"10.1016\/j.jaci.2014.12.987","article-title":"Site specific gene correction of defects in CD40 ligand using the Crispr\/Cas9 genome editing platform","volume":"135","author":"Kuo","year":"2015","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib96","doi-asserted-by":"crossref","first-page":"10934","DOI":"10.1038\/ncomms10934","article-title":"Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system","volume":"7","author":"Cheong","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.09.028_bib97","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.celrep.2015.08.013","article-title":"Modeling human severe combined immunodeficiency and correction by CRISPR\/Cas9-enhanced gene targeting","volume":"12","author":"Chang","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib98","doi-asserted-by":"crossref","first-page":"eaav4324","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells","volume":"5","author":"Min","year":"2019","journal-title":"Sci. Adv"},{"key":"10.1016\/j.ymthe.2020.09.028_bib99","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1242\/jcs.02952","article-title":"Severe muscular dystrophy in mice that lack dystrophin and \u03b17 integrin","volume":"119","author":"Rooney","year":"2006","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ymthe.2020.09.028_bib100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/hmg\/ddl018","article-title":"Absence of \u03b17 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy","volume":"15","author":"Guo","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib101","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In\u00a0vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib102","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In\u00a0vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib103","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib104","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1038\/ncomms7244","article-title":"Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy","volume":"6","author":"Ousterout","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.09.028_bib105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","article-title":"CRISPR\/Cas9-induced (CTG\u22c5CAG) n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing","volume":"25","author":"van Agtmaal","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib106","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in\u00a0vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2020.09.028_bib107","doi-asserted-by":"crossref","first-page":"eaay6812","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv"},{"key":"10.1016\/j.ymthe.2020.09.028_bib108","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk","volume":"132","author":"Bergeron","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2020.09.028_bib109","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in\u00a0vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib110","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/ATVBAHA.118.311221","article-title":"Somatic editing of Ldlr with adeno-associated viral-CRISPR is an efficient tool for atherosclerosis research","volume":"38","author":"Jarrett","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1242\/dmm.035469","article-title":"Effective CRISPR\/Cas9-based nucleotide editing in zebrafish to model human genetic cardiovascular disorders","volume":"11","author":"Tessadori","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2020.09.028_bib112","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2020.09.028_bib113","first-page":"4566","article-title":"Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib114","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in\u00a0vitro and in\u00a0vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib115","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1126\/science.7638621","article-title":"A familial Alzheimer\u2019s disease locus on chromosome 1","volume":"269","author":"Levy-Lahad","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib116","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.scr.2016.09.018","article-title":"Generation of a gene-corrected isogenic control hiPSC line derived from a familial Alzheimer\u2019s disease patient carrying a L150P mutation in presenilin 1","volume":"17","author":"Poon","year":"2016","journal-title":"Stem Cell Res. (Amst.)"},{"key":"10.1016\/j.ymthe.2020.09.028_bib117","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omtn.2018.03.007","article-title":"CRISPR\/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer\u2019s disease","volume":"11","author":"Gy\u00f6rgy","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2020.09.028_bib118","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.ymthe.2018.02.023","article-title":"Efficient in\u00a0vivo liver-directed gene editing using CRISPR\/Cas9","volume":"26","author":"Singh","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib119","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3469","article-title":"A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice","volume":"34","author":"Yang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-319-55780-9_2","article-title":"Biochemical and clinical aspects of hereditary tyrosinemia type 1","volume":"959","author":"Morrow","year":"2017","journal-title":"Adv. Exp. Med. Biol"},{"key":"10.1016\/j.ymthe.2020.09.028_bib121","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7754\/Clin.Lab.2014.141009","article-title":"Clinical and biochemical profile of tyrosinemia type 1 in Tunisia","volume":"61","author":"Nasrallah","year":"2015","journal-title":"Clin. Lab."},{"key":"10.1016\/j.ymthe.2020.09.028_bib122","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nbt.2884","article-title":"Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype","volume":"32","author":"Yin","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib123","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1089\/hum.2017.252","article-title":"Curative ex\u00a0vivo hepatocyte-directed gene editing in a mouse model of hereditary tyrosinemia type 1","volume":"29","author":"VanLith","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-018-06195-6","article-title":"First test of in-body gene editing shows promise","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.028_bib126","article-title":"New gene-editing treatment might help treat a rare disorder, hints first human test","author":"Kaiser","year":"2018","journal-title":"Science Magazine, September 5, 2018"},{"key":"10.1016\/j.ymthe.2020.09.028_bib127","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/apm.12915","article-title":"Cystic fibrosis\u2014an example of personalized and precision medicine","volume":"127","author":"Skov","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.ymthe.2020.09.028_bib128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fphar.2018.00396","article-title":"Innovative therapeutic strategies for cystic fibrosis: moving forward to CRISPR technique","volume":"9","author":"Marangi","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib129","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stemcr.2015.02.005","article-title":"Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells","volume":"4","author":"Crane","year":"2015","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.ymthe.2020.09.028_bib130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123529","article-title":"A sheep model of cystic fibrosis generated by CRISPR\/Cas9 disruption of the CFTR gene","volume":"3","author":"Fan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2020.09.028_bib131","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-genet-102108-134222","article-title":"How the fanconi anemia pathway guards the genome","volume":"43","author":"Moldovan","year":"2009","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib132","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/ijms18061269","article-title":"CRISPR\/Cas9-mediated correction of the FANCD1 gene in primary patient cells","volume":"18","author":"Skvarova Kramarzova","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2020.09.028_bib133","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1089\/scd.2016.0149","article-title":"CRISPR\/Cas9 targeted gene editing and cellular engineering in Fanconi anemia","volume":"25","author":"Osborn","year":"2016","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.ymthe.2020.09.028_bib134","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41588-018-0174-0","article-title":"CRISPR-Cas9 genome editing in human cells occurs via the Fanconi anemia pathway","volume":"50","author":"Richardson","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-genom-083117-021320","article-title":"Sickle cell anemia and its phenotypes","volume":"19","author":"Williams","year":"2018","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib136","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/5584_2018_331","article-title":"CRISPR\/Cas9 for sickle cell disease: applications, future possibilities, and challenges","volume":"1144","author":"Demirci","year":"2019","journal-title":"Adv. Exp. Med. Biol"},{"key":"10.1016\/j.ymthe.2020.09.028_bib137","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00439-016-1688-0","article-title":"Use of genome-editing tools to treat sickle cell disease","volume":"135","author":"Tasan","year":"2016","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib138","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/sci.2016.11.05","article-title":"Efficient CRISPR\/Cas9-based gene correction in induced pluripotent stem cells established from fibroblasts of patients with sickle cell disease","volume":"3","author":"Sato","year":"2016","journal-title":"Stem Cell Investig."},{"key":"10.1016\/j.ymthe.2020.09.028_bib139","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/mt.2016.148","article-title":"CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+ cells","volume":"24","author":"Hoban","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib140","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1073\/pnas.1612075113","article-title":"Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and \u03b2-thalassemia","volume":"113","author":"Ye","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.09.028_bib141","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","article-title":"Beta-thalassemia","volume":"12","author":"Cao","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib142","doi-asserted-by":"crossref","first-page":"046103","DOI":"10.1063\/1.5048625","article-title":"Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR\/Cas9-double nickase reveals potential safety concerns","volume":"2","author":"Alateeq","year":"2018","journal-title":"APL Bioeng."},{"key":"10.1016\/j.ymthe.2020.09.028_bib143","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/IAE.0000000000002649","article-title":"Visual impairment in retinitis pigmentosa","volume":"40","author":"Vezinaw","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2020.09.028_bib144","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.optm.2008.01.026","article-title":"Review and update: current treatment trends for patients with retinitis pigmentosa","volume":"80","author":"Shintani","year":"2009","journal-title":"Optometry"},{"key":"10.1016\/j.ymthe.2020.09.028_bib145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cccn.2004.08.004","article-title":"Gene mutations in retinitis pigmentosa and their clinical implications","volume":"351","author":"Wang","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymthe.2020.09.028_bib146","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s10038-017-0352-4","article-title":"In\u00a0vivo genome editing via the HITI method as a tool for gene therapy","volume":"63","author":"Suzuki","year":"2018","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib147","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In\u00a0vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.028_bib148","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exer.2016.06.011","article-title":"Mutations and mechanisms in congenital and age-related cataracts","volume":"156","author":"Shiels","year":"2017","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib149","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archopht.125.2.165","article-title":"Genetic origins of cataract","volume":"125","author":"Shiels","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/1120672118804757","article-title":"A novel missense mutation of GJA8 causes congenital cataract in a large Mauritanian family","volume":"29","author":"Hadrami","year":"2019","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib151","doi-asserted-by":"crossref","first-page":"22024","DOI":"10.1038\/srep22024","article-title":"CRISPR\/Cas9-mediated GJA8 knockout in rabbits recapitulates human congenital cataracts","volume":"6","author":"Yuan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib152","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1743-422X-11-92","article-title":"Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT\/enhancer binding protein site I","volume":"11","author":"Shah","year":"2014","journal-title":"Virol. J."},{"key":"10.1016\/j.ymthe.2020.09.028_bib153","doi-asserted-by":"crossref","first-page":"31527","DOI":"10.1038\/srep31527","article-title":"Negative feedback regulation of HIV-1 by gene editing strategy","volume":"6","author":"Kaminski","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib154","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1089\/hum.2018.018","article-title":"CRISPR\/Cas9 inhibits multiple steps of HIV-1 infection","volume":"29","author":"Yin","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41596-018-0069-7","article-title":"CRISPR-Cas9 genome engineering of primary CD4+ T\u00a0cells for the interrogation of HIV-host factor interactions","volume":"14","author":"Hultquist","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2020.09.028_bib156","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20190287","article-title":"HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells","volume":"216","author":"Hartweger","year":"2019","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib157","doi-asserted-by":"crossref","first-page":"E7249","DOI":"10.1073\/pnas.1516305112","article-title":"Specific induction of endogenous viral restriction factors using CRISPR\/Cas-derived transcriptional activators","volume":"112","author":"Bogerd","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.09.028_bib158","doi-asserted-by":"crossref","first-page":"e0191709","DOI":"10.1371\/journal.pone.0191709","article-title":"Editing of the human TRIM5 gene to introduce mutations with the potential to inhibit HIV-1","volume":"13","author":"Dufour","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2020.09.028_bib159","first-page":"258","article-title":"HBV cccDNA and its potential as a therapeutic target","volume":"7","author":"Zhu","year":"2019","journal-title":"J.\u00a0Clin. Transl. Hepatol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/genes9040207","article-title":"Gene therapy for chronic HBV\u2014can we eliminate cccDNA?","volume":"9","author":"Bloom","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2020.09.028_bib161","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/molecules24071349","article-title":"CRISPR\/Cas9-based antiviral strategy: current status and the potential challenge","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2020.09.028_bib162","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/srep13734","article-title":"CRISPR\/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X","volume":"5","author":"Karimova","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib163","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib164","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.7150\/thno.18114","article-title":"The gRNA-miRNA-gRNA ternary cassette combining CRISPR\/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication","volume":"7","author":"Wang","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2020.09.028_bib165","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.3748\/wjg.v24.i47.5297","article-title":"Hepatitis C: from inflammatory pathogenesis to anti-inflammatory\/hepatoprotective therapy","volume":"24","author":"Li","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib166","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature12048","article-title":"A CRISPR\/Cas system mediates bacterial innate immune evasion and virulence","volume":"497","author":"Sampson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.028_bib167","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1073\/pnas.1422340112","article-title":"Cas9-mediated targeting of viral RNA in eukaryotic cells","volume":"112","author":"Price","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.09.028_bib168","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2613.2001.00177.x","article-title":"Biology of human papillomaviruses","volume":"82","author":"McMurray","year":"2001","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib169","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1473-2165.2002.00419.x","article-title":"Human papillomavirus molecular biology and pathogenesis","volume":"16","author":"Sanclemente","year":"2002","journal-title":"J.\u00a0Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib170","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1128\/JVI.01879-14","article-title":"Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR\/Cas RNA-guided endonuclease","volume":"88","author":"Kennedy","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib171","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/1008-682X.157399","article-title":"Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6\/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes","volume":"18","author":"Liu","year":"2016","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.ymthe.2020.09.028_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2006.12.011","article-title":"Diagnostic evaluation of mononucleosis-like illnesses","volume":"120","author":"Hurt","year":"2007","journal-title":"Am. J. Med"},{"key":"10.1016\/j.ymthe.2020.09.028_bib173","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1099\/jgv.0.000012","article-title":"CRISPR\/Cas9-mediated genome editing of Epstein-Barr virus in human cells","volume":"96","author":"Yuen","year":"2015","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib174","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.chom.2017.04.005","article-title":"CRISPR\/Cas9 screens reveal Epstein-Barr virus-transformed B cell host dependency factors","volume":"10","author":"Ma","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ymthe.2020.09.028_bib175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1242\/dmm.024547","article-title":"Using the mouse to model human disease: increasing validity and reproducibility","volume":"9","author":"Justice","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2020.09.028_bib176","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nmeth.4259","article-title":"Addressing reproducibility in single-laboratory phenotyping experiments","volume":"14","author":"Kafkafi","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.09.028_bib177","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng0597-19","article-title":"Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice","volume":"16","author":"Simpson","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib178","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1523\/JNEUROSCI.23-12-05105.2003","article-title":"Factors in the genetic background suppress the engrailed-1 cerebellar phenotype","volume":"23","author":"Bilovocky","year":"2003","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2020.09.028_bib179","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature.2016.20988","article-title":"CRISPR gene-editing tested in a person for the first time","volume":"539","author":"Cyranoski","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.028_bib180","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T\u00a0cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib181","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T\u00a0cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.028_bib182","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","author":"Fousek","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2020.09.028_bib183","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3026(19)30169-3","article-title":"CRISPR-Cas9 gene editing for patients with haemoglobinopathies","volume":"6","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib184","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib185","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/d41586-020-00655-8","article-title":"CRISPR treatment inserted directly into the body for first time","volume":"579","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.028_bib186","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ymthe.2020.03.015","article-title":"Variability in genome editing outcomes: challenges for research reproducibility and clinical safety","volume":"28","author":"Teboul","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.028_bib187","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib188","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nbt.3127","article-title":"Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors","volume":"33","author":"Wang","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib189","doi-asserted-by":"crossref","first-page":"e1007503","DOI":"10.1371\/journal.pgen.1007503","article-title":"No unexpected CRISPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice","volume":"14","author":"Iyer","year":"2018","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymthe.2020.09.028_bib190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib191","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.09.028_bib192","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib193","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nbt.2908","article-title":"Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing","volume":"32","author":"Tsai","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib194","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-020-01893-z","article-title":"Mitigating off-target effects in CRISPR\/Cas9-mediated in\u00a0vivo gene editing","volume":"98","author":"Han","year":"2020","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.ymthe.2020.09.028_bib195","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.celrep.2015.01.016","article-title":"Deletions, inversions, duplications: engineering of structural variants using CRISPR\/Cas in mice","volume":"10","author":"Kraft","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2020.09.028_bib196","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s42003-019-0321-x","article-title":"A large CRISPR-induced bystander mutation causes immune dysregulation","volume":"2","author":"Simeonov","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib197","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib198","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1111\/febs.13416","article-title":"Inhibition of nonhomologous end joining to increase the specificity of CRISPR\/Cas9 genome editing","volume":"282","author":"Vartak","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.ymthe.2020.09.028_bib199","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in\u00a0vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2020.09.028_bib200","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3198","article-title":"Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells","volume":"33","author":"Chu","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib201","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0038-1634861","article-title":"A new paradigm of medical informatics","volume":"31","author":"Seelos","year":"1992","journal-title":"Methods Inf. Med."},{"key":"10.1016\/j.ymthe.2020.09.028_bib202","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/v11010028","article-title":"Viral delivery systems for CRISPR","volume":"11","author":"Xu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2020.09.028_bib203","first-page":"197","article-title":"CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges","volume":"1866","author":"Yi","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2020.09.028_bib204","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","article-title":"In\u00a0vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease","volume":"6","author":"Lau","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib205","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1101\/gr.231936.117","article-title":"CRISPR RNAs trigger innate immune responses in human cells","volume":"28","author":"Kim","year":"2018","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib206","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10529-016-2064-9","article-title":"Improved delivery of Cas9 protein\/gRNA complexes using lipofectamine CRISPRMAX","volume":"38","author":"Yu","year":"2016","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ymthe.2020.09.028_bib207","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.4081\/ejh.2019.3048","article-title":"Comparison between Lipofectamine RNAiMAX and GenMute transfection agents in two cellular models of human hepatoma","volume":"63","author":"Berardo","year":"2019","journal-title":"Eur. J. Histochem"},{"key":"10.1016\/j.ymthe.2020.09.028_bib208","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1073\/pnas.1520244113","article-title":"Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.09.028_bib209","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1166\/jbn.2018.2604","article-title":"Transfection of difficult-to-transfect rat primary cortical neurons with magnetic nanoparticles","volume":"14","author":"Jin","year":"2018","journal-title":"J.\u00a0Biomed. Nanotechnol."},{"key":"10.1016\/j.ymthe.2020.09.028_bib210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-1-4939-6518-2_7","article-title":"Cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA for genome editing","volume":"1507","author":"Suresh","year":"2017","journal-title":"Methods Mol. Biol"},{"key":"10.1016\/j.ymthe.2020.09.028_bib211","doi-asserted-by":"crossref","first-page":"12029","DOI":"10.1002\/anie.201506030","article-title":"Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing","volume":"54","author":"Sun","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2020.09.028_bib212","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/anie.201708689","article-title":"Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy","volume":"57","author":"Wang","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2020.09.028_bib213","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2004.04.024","article-title":"Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method","volume":"98","author":"Kogure","year":"2004","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2020.09.028_bib214","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1021\/ar200254s","article-title":"A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications","volume":"45","author":"Nakamura","year":"2012","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ymthe.2020.09.028_bib215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000003327","article-title":"Genetically modified babies and a first application of clustered regularly interspaced short palindromic repeats (CRISPR-Cas9)","volume":"134","author":"Rose","year":"2019","journal-title":"Obstet. Gynecol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620304858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620304858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:58:05Z","timestamp":1761501485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620304858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":215,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1525001620304858"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.028","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}